A complete application in a minute — tailored resume and cover letter, ready to send.
Quetzal Therapeutics seeks an experienced contractor Medical Science Liaison (MSL) to support a multinational Phase 3 haematology/oncology trial across Italy and Germany. The role emphasizes scientific engagement with investigators, trial awareness, and compliant exchange within regulatory and SOP frameworks.
The candidate will operate across a distributed territory, travel 70–80% of the time, and collaborate with Medical Affairs, Clinical Operations, and other teams to communicate insights and
Quetzal Therapeutics is a biopharmaceutical company focused on the development of treatment for rare diseases including hematologic malignancies. The company’s lead product is QTX-2101, a novel paradigm for treating patients with Acute Promyelocytic Leukemia (APL) for which the company initiated a Phase III clinical trial in December 2025. Quetzal is also developing a pre-clinical asset QTX-2102, an advanced, next-generation antifungal and antiparasitic therapy designed to enhance efficacy while minimizing toxicity. Our mission is to push the boundaries of treatment possibilities, delivering hope and life-changing solutions to those who need them most.
We are seeking an experienced contractor Medical Science Liaison (MSL) to support a multinational Phase 3 haematology/oncology clinical trial across Italy and Germany. This field-based role will focus on scientific engagement with investigators and treatment centres, supporting trial awareness, operational engagement, and high-quality scientific exchange within a compliant framework.
The successful candidate will work independently across a geographically distributed territory and act as a key scientific interface between the company and external stakeholders.
Primary territories:
Travel within the assigned territory and attendance at relevant scientific meetings/congresses will be required.
Approximately 70–80% field-focused activity expected.